Cardiovascular Complications and COVID-19 (CovCardioVasc-Study)

Conditions

Acute Coronary Syndrome, COVID, Deep Vein Thrombosis, Myocardial Infarction, Myocarditis, Pulmonary Embolism, Venous Thromboembolism

Brief summary

Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.

Jozwiak M, Dupuis C, Denormandie P, Aurenche Mateu D, Louchet J, Heme N, Mira JP, Doyen D, Dellamonica J.

2024-01-231 citations

10.1186/s13613-024-01248-8

Impact of sex differences on cardiac injury in critically ill patients with COVID-19.

Jozwiak M, Doyen D, Denormandie P, Goury A, Marey J, Pène F, Cariou A, Mira JP, Dellamonica J, Nguyen LS.

2023-11-20

10.1186/s12931-023-02581-5

High Prevalence of Acquired Thrombophilia Without Prognosis Value in Patients With Coronavirus Disease 2019

Émile Ferrari, Benjamin Sartre, Fabien Squara, Julie Contenti, Céline Occelli et al. (21 authors)

Journal of the American Heart Association2020-09-2550 citations

10.1161/jaha.120.017773

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

\- All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be included

Exclusion criteria

\- Patients under 18 years

Design outcomes

Primary

Measure	Time frame	Description
Determine the incidence of cardiomyopathies and venous thromboembolism	28 days	Incidence of cardiomyopathies and/or venous thromboembolism at day 28

Secondary

Measure	Time frame	Description
Duration of mechanical ventilation	hospitalisation duration	Number of day of using mechanical ventilation for each patients
Shock	hospitalisation duration	Incidence of shock during hospitalisation
Mortality	28 days	Incidence of mortality at day 28
Mechanical ventilation	hospitalisation duration	Setting up or not of mechanical ventilation
Renal replacement therapy	hospitalisation duration	Administration or not of renal replacement therapy
length of stay	hospitalisation duration	Number of day at hospital

Countries

France

Outcome results